Menu

Elder Pharmaceuticals

Elder Pharmaceuticals Limited was an Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company was engaged in the manufacture and marketing of formulations, active pharmaceutical ingredients (APIs) and nutraceutical products, and built a portfolio that included several brands in the women's healthcare, pain management and lifestyle segments of the Indian market.

Key facts

Name Elder Pharmaceuticals Limited
Type Public limited company
Industry Pharmaceuticals
Headquarters Mumbai, Maharashtra, India
Country India
Products Formulations, active pharmaceutical ingredients, nutraceuticals

Background

Elder Pharmaceuticals operated as a mid-sized Indian drug maker, with a presence in branded formulations for the domestic market alongside an API business that supplied bulk drugs. The company developed a marketing-led model, building recognised brands in therapeutic areas such as women's health, wound care, pain management and nutritional supplements. In addition to its India-focused formulations division, Elder also pursued exports of bulk actives and finished products.

Operations

The company's business was broadly organised into two streams:

  • Formulations: Branded prescription and over-the-counter products marketed in India through a field force of medical representatives.
  • Active pharmaceutical ingredients: Manufacture of bulk drugs for captive use and for sale to other formulators in India and overseas markets.

Divestment of branded business

In a significant restructuring, Elder Pharmaceuticals divested a major part of its Indian branded formulations portfolio to Torrent Pharmaceuticals. The transaction transferred a set of leading brands and associated trademarks to Torrent, marking one of the larger domestic-formulations deals in the Indian pharmaceutical industry at the time and reshaping Elder's product footprint in India.

Significance

Elder Pharmaceuticals is recognised in the history of the Indian pharmaceutical sector for its brand-building approach in niche therapeutic segments and for the scale of its eventual divestment of branded formulations. The company is often cited as an example of mid-cap Indian pharma firms that grew through focused therapeutic franchises before consolidating their portfolios through sale to larger industry players.

References